|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
A role for CD40-CD40L interactions has been identified in atherosclerosis, and such interactions are known to destabilize atherosclerotic plaques by inducing the expression of cytokines, chemokines, growth factors, matrix metalloproteinases and pro-coagulant factors.
|
18977174 |
2008 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages.
|
10073974 |
1999 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Because CD40L is a potent platelet-derived cytokine that is involved in thrombosis and atherosclerosis, we evaluated the effect of GPVI-mediated release of CD40L on activation of endothelial cells.
|
15277394 |
2004 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The CD40/CD40L dyad is deemed to play a central role in several inflammatory processes, including atherosclerosis.
|
23896727 |
2013 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, abnormal expression of CD154 has been hypothesized to contribute to a wider array of diseases, from atherosclerosis to Alzheimer's disease.
|
12857968 |
2003 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Ligands of this family comprise multiple important cytokines such as TNFα, CD40L, and interleukin-1β that promote chronic inflammatory diseases such as atherosclerosis.
|
20651286 |
2010 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Costimulatory molecules of the tumor necrosis factor superfamily such as CD40/CD40L and OX40/OX40L have been implicated in atherosclerosis.
|
18285570 |
2008 |
|
Atherosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of genetic variation in CD40 and CD40L genes in subclinical atherosclerosis assessed by coronary artery calcification (CAC) and carotid intima-media thickness in 620 individuals from 230 families in the DHS.
|
16504636 |
2006 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
This study investigated the role of CD40L in pro-inflammatory gene expression and cellular differentiation in adipose tissue to obtain insight into mechanisms linking the MS with atherosclerosis.
|
20174757 |
2010 |
|
Atherosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Homozygosity for the C allele of the -1T>C SNP of the CD40 gene (rs1883832) results in an enhanced CD40 surface abundance and pro-inflammatory phenotype of vascular endothelial cells, increasing the susceptibility to atherosclerosis and CHD in humans.This appears to be compensated by an enhanced shedding of sCD40 from the endothelial cell membrane to neutralize excess CD40 ligand. sCD40 might be a potential new biomarker for the pro-inflammatory processes occurring in atherosclerosis.
|
31373353 |
2019 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
1.CD40 and CD40 ligand (CD40L) have a critical role in the pathophysiology and risk prediction of coronary artery syndrome, including atherothrombosis and atherosclerosis.
|
20456428 |
2010 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Administration of antibody against CD154 to low-density lipoprotein receptor-deficient mice has been shown to reduce atherosclerosis and decrease T-lymphocyte and macrophage content; however, only initial lesions were studied.
|
10546000 |
1999 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Increased Levels of Oxidative Stress Markers, Soluble CD40 Ligand, and Carotid Intima-Media Thickness Reflect Acceleration of Atherosclerosis in Male Patients with Ankylosing Spondylitis in Active Phase and without the Classical Cardiovascular Risk Factors.
|
28883908 |
2017 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Strong evidence supports a role for CD40 ligand (CD40L) as marker and mediator of inflammatory diseases such as atherosclerosis.
|
17372166 |
2007 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Specific inhibition of CD40L-Mac-1 binding may represent an attractive anti-inflammatory treatment strategy for atherosclerosis and other inflammatory conditions, potentially avoiding the unwanted immunologic and thrombotic effects of global inhibition of CD40L.
|
21998326 |
2011 |
|
Atherosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Although we did not observe a significant association of CD40-CD154 gene variants with the development of CV events, an ANCOVA model adjusted for sex, age at the time of the ultrasonography assessment, follow-up time, traditional CV risk factors and anti-cyclic citrullinated peptide antibodies disclosed a significant association (p=0.0047) between CD40 rs1535045 polymorphism and carotid intima media thickness, a surrogate marker of atherosclerosis.
|
23166616 |
2012 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The relationship between soluble CD40 ligand level and atherosclerosis in white-coat hypertension.
|
29162926 |
2017 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Platelet cluster of differentiation 40 (CD40) ligand (CD40L and CD154) plays a key role in mediating platelet-induced inflammation in atherosclerosis.
|
26821950 |
2016 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Disrupting the costimulatory CD40-CD40L dyad reduces atherosclerosis, but can result in immune suppression.
|
29406859 |
2018 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The CD40 receptor and its ligand (CD40L) are known to modulate both inflammation and thrombosis-2 processes important for the development and clinical expression of atherosclerosis.
|
19061720 |
2008 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
A role for platelet CD40L in mediating thrombotic and inflammatory processes in atherosclerosis has also been reported.
|
24030045 |
2014 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The recent recognition of platelets as an abundant source of CD40L led to a reassessment of the involvement of CD40L in atherosclerosis.
|
14517846 |
2003 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Biomarkers of endothelial dysfunction such as endoglin (in the control group: 3.85+/-1.25 microg/l, in lipoprotein apheresis-treated hypercholesterolemic individuals 5.74+/-1.47 microg/l), CD40 ligand (before lipoprotein apheresis: 6498+/-2529 ng/l, after lipoprotein apheresis: 4057+/-2560 ng/l) and neopterin (before lipoprotein apheresis: 5.7+/-1.1 nmol/l, after lipoprotein apheresis: 5.5+/-1.3 nmol/l) related to the course of atherosclerosis, but did not reflect the actual activity of the disease nor facilitate the prediction or planning of therapy.
|
28379034 |
2017 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Indeed, blockade of CD40L by neutralizing antibodies or genetic disruption in mice prevents atherosclerosis and atherothrombosis.
|
26719354 |
2017 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Costimulatory cascades such as the CD40L-CD40 dyad enhance immune cell activation and inflammation during atherosclerosis.
|
24664276 |
2014 |